Not yet recruitingOBSERVATIONAL

Acute Kidney Injury : Long-term Renal and Cardiovascular Prognosis and Biomarker-based Risk Assessment

If you've had a serious kidney injury while in intensive care, you might be at higher risk for heart or kidney problems later on. This study is trying to understand why and how to better identify those risks. We're looking at specific substances in the blood, called biomarkers (galectin-3 and CD146), measured during the kidney injury. The main goal is to see if these biomarkers can help predict if someone will develop heart attacks, strokes, severe chronic kidney disease, or need dialysis in the long term. We're also checking how these biomarkers relate to other kidney and heart problems, helping us to better care for people after a severe kidney injury.

At a glance

Status

Not yet recruiting

Sponsor

Assistance Publique - Hôpitaux de Paris

Enrolment target

412

Start

01 Jun 2026

Estimated completion

30 May 2027

Renal Injury, Acute

What is this study about?

This research is looking into what happens to people long after they've had a serious kidney injury (Acute Kidney Injury, or AKI) while they were in intensive care. We know that these patients often face a higher risk of developing serious long-term health problems. These can include ongoing kidney issues, needing dialysis, or even heart problems like heart attacks and strokes. Sadly, current methods don't always do a great job of predicting which patients will experience these problems.

The main aim of this study is to find better ways to predict these long-term risks. We are studying special substances in the blood, called biomarkers (galectin-3 and CD146). These were measured when patients were first ill. We want to see if these biomarkers can help us understand who might be at higher risk of future kidney or heart complications, or even death, after they've recovered from the initial severe kidney injury.

By understanding this better, doctors might be able to identify patients at higher risk earlier. This could lead to more personalised care and interventions to prevent these serious long-term health issues and ultimately improve the health and well-being of people who have experienced severe kidney injury.

Key takeaways

This study focuses on people who had a severe kidney injury in intensive care.
It aims to predict long-term heart and kidney problems using special blood markers.
We are using existing blood samples and health information, not new treatments.
The goal is to improve future care for patients after kidney injury.
Participation involves providing health updates, often by phone.
There are no direct risks from taking part in this study.

Who may be eligible?

To be part of this study, you must have been a patient in a previous study called AKIKI 2. Importantly, you also need to have been alive 60 days after starting the AKIKI 2 study.

We cannot include you in this study if you do not wish to take part. It's important that you feel comfortable and agree to participate.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

I was enrolled in the AKIKI 2 study.
I was alive 60 days after starting the AKIKI 2 study.
I am comfortable with my existing health information and blood samples being used for this research.
I am willing to provide updates on my health, likely through phone calls, if asked.

Answer every question to see your result.

What does participation involve?

If you're eligible and agree to take part, your involvement will mostly be about us collecting information. We won't be giving you new medicines or treatments as part of this study. Your blood samples that were taken during the original AKIKI 2 study will be used to look for the specific biomarkers. We will also contact you by telephone, or speak with your local doctor, to gather updates on your health after leaving the hospital. This will help us understand if you've developed any heart or kidney problems. If needed, we might recommend you see a heart specialist as part of your usual care. We'll be collecting information from when you were first in the AKIKI 2 study up until now, for the full duration of our follow-up.

Potential risks and benefits

There are no direct medical risks from participating in this study as we are using existing blood samples and gathering information, not performing new procedures or giving new medications. The potential benefit is that the study could lead to a better understanding of long-term risks for people who have had severe kidney injury, which might improve future patient care. You have the right to withdraw your consent to participate at any time without affecting your medical care.

Locations (1)

Réanimation médico-chirurgicale, Hôpital Avicenne
Verified postcode
Bobigny, France

Common questions

What is 'Acute Kidney Injury'?

Acute Kidney Injury, or AKI, means your kidneys suddenly stop working properly. It can range from a slight loss of kidney function to complete kidney failure.

What are 'biomarkers'?

Biomarkers are simply a way of saying we're looking for specific substances in your blood that can tell us more about your health or risks. In this study, we're looking at galectin-3 and CD146.

Will I get any special treatment in this study?

No, this study doesn't involve new treatments. We're looking at existing information and blood samples to understand health risks.

What kind of long-term risks are you looking for?

We're focusing on serious heart problems like heart attacks or strokes, and serious kidney problems like needing dialysis or developing severe chronic kidney disease.

Who is funding this research?

The information provided does not specify the funding source for this research.

How to find out more

Khalil CHAIBI, Dr

khalil.chaibi@aphp.fr 00 33 1 48 95 52 41 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.